Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a clinical research protocol to study the efficacy of combined varenicline (Chantix) and motivational interviewing (MI) for smoking cessation in a sample of smokers who have been diagnosed with schizophrenia or schizoaffective disorder. The study is a double-blind, randomized, controlled, subacute treatment trial of MI plus varenicline (VAR-MI) versus MI plus placebo (PLA-MI). The pharmaceutical treatment will utilize Chantix at a dose of 1 mg/day for a period of two weeks.

The primary goal is to determine if VAR-MI decreases baseline behavioral measures of urge and withdrawal and reduces baseline rates of cigarette consumption. The primary efficacy measures of VAR-MI vs. PLA-MI treatment are: Minnesota Nicotine Withdrawal Scale, Questionnaire for Smoking Urge-brief, number of cigarettes smoked per day in the previous week, CO levels, and Brief Psychiatric Rating Scale and Positive And Negative Symptom Scale scores on the last day of the study. Other primary outcome measures are to determine the effects of VAR-MI and PLA-MI on smoking cue-induced urges in tobacco cue reactivity sessions and reward responsiveness as assessed by a computerized task.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

NCT00621777

Schizophrenia Schizoaffective Disorder Bipolar Disorder +1 more

COMPLETED PHASE4

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969

Smoking Cessation

COMPLETED PHASE3

Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia

NCT01850953

Craving Smoking Schizophrenia

COMPLETED PHASE4

Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia

NCT01093365

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE2

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

NCT03507127

Tobacco Dependence

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.

Group Type EXPERIMENTAL

varenicline

Intervention Type DRUG

.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.

Adaptation of Motivational Interviewing

Intervention Type BEHAVIORAL

2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.

2

PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.

Group Type PLACEBO_COMPARATOR

Adaptation of Motivational Interviewing

Intervention Type BEHAVIORAL

2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

varenicline

.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.

Intervention Type DRUG

Adaptation of Motivational Interviewing

2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Eligible participants for this study:

* Are between the ages 18-65 years of age
* Are daily cigarette smokers
* Have smoked a minimum of 10 cigarettes per day for at least one year
* Are confirmed smokers as verified by CO
* Have a psychiatric diagnosis of schizophrenia or schizoaffective disorder (any subtype) as determined by the SCID-IV. Participants must have received a stable dose of antipsychotic medication for at least 2 weeks prior to beginning the study. Patients receiving clozapine at 500 mg/day or more must also be receiving anti-seizure prophylaxis. Patients must be determined to be psychiatrically stable at baseline as established by standardized interview and medical review by psychiatrist.

Exclusion Criteria

Individuals who are not eligible to participate in this study include individuals with:

* Any serious or unstable medical problem in the last 6 months
* Severe renal impairment
* A history of clinically significant allergic reactions to nicotine agonist medications
* Current primary use of tobacco products other than cigarettes
* Breath alcohol level \> 0.005 g/l at screening
* Current substance abuse or dependence (besides nicotine)
* Current attempts to quit smoking using any method
* Designation as legally incompetent to sign the informed consent (i.e., have a guardian or have delegated power of attorney to another).

Other exclusions are:

* Current use of medications that might affect the behavioral response to cigarette smoking, including transdermal nicotine or nicotine gum and bupropion - Inability to participate in the screening session due to severe psychosis, severe depression or suicidality, current mania, or an organic mental disorder such as dementia or delirium
* Presence of unstable psychiatric symptoms or clinical deterioration (i.e., unstable psychosis, homicidality, or suicidality) within the last month.
* Females of childbearing potential are eligible if not pregnant or nursing and if they practice effective contraception (oral, injectable, or implantable contraceptives; intrauterine device; or barrier method with spermicide).
* There currently are no known contraindications to the use of varenicline and no identified drug-drug interactions. However, reduced dosage of varenicline is recommended for individuals with severe renal impairment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No